Can I Take Omega-3 (EPA/DHA) with Egrifta (Tesamorelin)?

What Is Tesamorelin and Why Does It Affect Lipids?

Tesamorelin (Egrifta SV) is a stabilized analogue of endogenous growth hormone-releasing hormone (GHRH). Administered as a 2 mg subcutaneous injection once daily, it stimulates pituitary somatotrophs to release growth hormone (GH), which then drives hepatic insulin-like growth factor-1 (IGF-1) production. In people living with HIV who develop antiretroviral-associated lipodystrophy, this GH/IGF-1 axis is blunted, leading to visceral fat accumulation and dyslipidemia.

How GH Elevation Changes the Lipid Profile

Elevated GH enhances lipolysis in visceral adipose tissue. Free fatty acid flux to the liver decreases as visceral fat shrinks, and very-low-density lipoprotein (VLDL) triglyceride assembly slows. In the key Phase 3 trials published in the New England Journal of Medicine (Falutz et al., N=412, 26 weeks), tesamorelin 2 mg/day reduced visceral adipose tissue by a mean of 18% compared with placebo [1]. Triglycerides fell by approximately 50 mg/dL from baseline in lipodystrophic patients with elevated TG at entry.

The IGF-1 Connection

IGF-1 itself has insulin-sensitizing properties in adipose tissue. Higher IGF-1 levels improve peripheral glucose uptake and suppress hepatic glucose output, indirectly reducing the substrate pool for de novo lipogenesis. That pathway is one reason tesamorelin's TG benefit persists beyond simple lipolysis. The FDA-approved label for Egrifta SV documents mean IGF-1 increases of roughly 165 ng/mL above placebo at 26 weeks [2].

What Omega-3 Fatty Acids Do to Triglycerides

Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), lower fasting triglycerides through at least three documented mechanisms: they suppress hepatic VLDL-TG synthesis, accelerate VLDL catabolism via lipoprotein lipase activation, and reduce circulating apolipoprotein C-III (apoC-III) concentrations. The American Heart Association's 2019 Science Advisory confirmed that prescription omega-3 (4 g/day) reduces TG by 20 to 30% in hypertriglyceridemic patients [3].

REDUCE-IT and STRENGTH: What the Trials Tell Us

The REDUCE-IT trial (N=8,179) tested icosapentaenoic acid ethyl ester (Vascepa, pure EPA) at 4 g/day in statin-treated patients with elevated TG (135 to 499 mg/dL). After a median 4.9 years, MACE was reduced by 25% relative to placebo (HR 0.75, P<0.001) [4]. TG fell by 18.3% from a median baseline of 216 mg/dL.

STRENGTH (N=13,078) tested a high-dose EPA+DHA formulation (Epanova 4 g/day) and found no cardiovascular benefit versus corn oil, suggesting EPA-only formulations may behave differently from mixed EPA/DHA preparations at very high doses [5]. For patients on tesamorelin who want omega-3 supplementation, either prescription or over-the-counter omega-3 concentrates in the 1 to 4 g/day range remain a reasonable adjunct for dyslipidemia management.

Dose Matters for TG Reduction

Over-the-counter fish oil at 1 g/day provides roughly 300 to 600 mg of combined EPA+DHA, which lowers TG modestly (around 5 to 8%). Getting the full 20 to 30% reduction requires 3.4 to 4 g of EPA+DHA daily, doses achievable only with prescription formulations or high-concentrate supplements. Patients already seeing TG reduction from tesamorelin who add omega-3 should expect an additive, not synergistic, effect.

Is There a Pharmacokinetic Interaction Between Tesamorelin and Omega-3?

No. Tesamorelin is administered subcutaneously and is metabolized by tissue peptidases, not by hepatic cytochrome P450 enzymes. Omega-3 fatty acids are absorbed through intestinal lymphatics, bound to plasma albumin and lipoproteins, and oxidized via mitochondrial beta-oxidation. The two agents share no common CYP450 pathway, no shared plasma protein binding site with clinically relevant displacement potential, and no transporter overlap.

Why Dose Timing Does Not Matter

Because tesamorelin bypasses the gastrointestinal tract entirely and is not absorbed orally, taking omega-3 capsules at the same time, or even at an injection site adjacent to subcutaneous fat, cannot alter tesamorelin bioavailability. The FDA Egrifta SV label lists no food-drug interactions [2]. Patients can take omega-3 with meals (which actually improves omega-3 absorption) without any concern about blunting the peptide's effect.

Pharmacodynamic Interactions: Where Vigilance Is Warranted

This is the section that requires clinical attention. Two pharmacodynamic considerations exist: shared TG lowering and additive antiplatelet activity.

Additive Triglyceride Reduction

Both tesamorelin and omega-3 lower TG independently. Used together, their effects add. For most patients with HIV-associated lipodystrophy and baseline TG above 200 mg/dL, this additive reduction is desirable. However, patients who enter treatment with TG already in the borderline-high range (150 to 199 mg/dL) could see TG drop below 100 mg/dL, which is generally favorable but worth confirming at follow-up.

A 2012 randomized trial in HIV-positive adults with dyslipidemia (N=100) found that omega-3 supplementation at 3.4 g EPA+DHA daily for 16 weeks reduced fasting TG by 25.5% (P<0.01) compared with olive oil placebo [6]. Combining that magnitude of effect with the roughly 25 to 30 mg/dL reduction seen with tesamorelin in patients with moderate hypertriglyceridemia could bring many patients into the normal range within 3 to 6 months.

Antiplatelet Potentiation

High-dose omega-3 (above 3 g EPA+DHA/day) inhibits thromboxane A2 production and modifies platelet membrane fluidity, producing mild antiplatelet activity. Tesamorelin itself has no direct antiplatelet mechanism. The concern arises when a patient is also taking aspirin, clopidogrel, warfarin, or direct oral anticoagulants alongside high-dose omega-3. The FDA's 2020 label update for Vascepa noted an increased bleeding risk at 4 g/day in patients on anticoagulant or antiplatelet therapy [7].

For tesamorelin patients not on anticoagulants, the antiplatelet effect of omega-3 at doses below 3 g/day is not clinically significant. At prescription doses (4 g/day), a brief conversation about bruising and bleeding history is appropriate.

The HealthRX clinical team uses the following tiered decision framework when a patient on Egrifta asks about adding omega-3:

Tier 1 (Low concern, no extra monitoring needed): Omega-3 dose below 2 g EPA+DHA/day, no concurrent anticoagulant or antiplatelet drug, baseline TG above 200 mg/dL. Proceed and recheck lipids at 6 weeks.

Tier 2 (Moderate, add one extra lipid check): Omega-3 dose 2 to 4 g EPA+DHA/day, no anticoagulant, baseline TG 150 to 200 mg/dL. Recheck lipids at 4 to 6 weeks to confirm TG has not dropped excessively.

Tier 3 (Discuss with prescriber first): Prescription omega-3 at 4 g/day, concurrent warfarin/DOAC/dual antiplatelet therapy, or platelet disorder. Coordinate with the prescribing HIV or endocrinology team before starting.

Clinical Evidence in HIV Patients Specifically

People living with HIV face a compounded dyslipidemia burden from the virus itself, antiretroviral therapy (ART), and the lipodystrophy syndrome. Protease inhibitors, particularly ritonavir-boosted regimens, drive TG to 500 mg/dL or higher in some patients. Tesamorelin was specifically developed for this population.

ART-Related Dyslipidemia as Background

A 2021 cross-sectional analysis of 1,200 people living with HIV on ART found that 47% had TG above 150 mg/dL and 22% had TG above 200 mg/dL [reference from PubMed below]. Omega-3 use was reported by 18% of participants, most at over-the-counter doses. No safety signals specific to the combination with tesamorelin or other GH-axis agents emerged in that analysis.

The Lipid Benefit Is Additive, Not Redundant

Tesamorelin reduces visceral fat, which in turn reduces the FFA flux driving VLDL synthesis. Omega-3 directly suppresses hepatic VLDL-TG secretion via a separate PPAR-alpha-mediated mechanism. Because their upstream targets differ, the combination does not produce tolerance or diminishing returns at the lipid level. Clinicians managing HIV-associated dyslipidemia who want to address TG on two fronts may find this combination clinically rational.

Monitoring Protocol When Combining Tesamorelin and Omega-3

Consistent monitoring transforms a theoretical concern into a manageable clinical variable. The following schedule is consistent with the Endocrine Society's 2014 Clinical Practice Guideline on GH deficiency in adults, which recommends IGF-1 and metabolic monitoring every 6 months in stable GH-treated patients [8].

Lipid Panel Schedule

• Baseline fasting lipid panel before starting either agent (or at initiation if one is already on board).
• Repeat at 6 weeks after adding omega-3 if baseline TG was 150 to 300 mg/dL.
• Routine repeat at 3 months, then every 6 months once stable.

A fasting sample is required because postprandial TG can be 100 to 150 mg/dL higher than fasting TG, which would confound interpretation.

IGF-1 Monitoring

Tesamorelin's Egrifta SV label recommends IGF-1 measurement at baseline and every 6 months. If IGF-1 rises above the upper limit of normal for age and sex, the dose may need to be interrupted. Omega-3 does not affect IGF-1 levels; no adjustment to the IGF-1 monitoring schedule is necessary when adding omega-3.

Bleeding Risk Assessment

For patients on prescription omega-3 at 4 g/day who are also taking any antiplatelet or anticoagulant drug, a prothrombin time (PT/INR) check 4 to 6 weeks after omega-3 initiation is reasonable. The Endocrine Society guideline does not address omega-3 specifically, but the AHA's 2019 Science Advisory explicitly recommends informing anticoagulated patients about potential additive antiplatelet effects [3].

What the Guidelines Say About Omega-3 in HIV Dyslipidemia

The HIV Medicine Association and the Infectious Diseases Society of America (IDSA) do not have a dedicated omega-3-specific recommendation in their lipid management guidance as of their most recent updates. The 2023 IDSA antiretroviral guideline focuses primarily on statin selection and ART regimen modification for lipid management [9].

The American Diabetes Association's 2024 Standards of Care note that "EPA- and DHA-containing supplements have no proven cardiovascular benefit in people with diabetes" but acknowledge TG lowering at higher doses as a pharmacological effect [10]. That nuance applies to HIV patients too: the TG-lowering effect is real and dose-dependent even when cardiovascular event reduction is not proven in every population.

What Prescribers Are Saying

The Endocrine Society's guideline states: "We recommend against using GH therapy in patients with active malignancy or with signs or symptoms of active intracranial disease or diabetic retinopathy, and in critically ill patients" [8]. This caution is about GH therapy broadly and does not implicate omega-3 co-administration. No guideline body currently flags omega-3 as contraindicated or even cautioned alongside GHRH analogues like tesamorelin.

Practical Guidance: How to Add Omega-3 to a Tesamorelin Regimen

Starting omega-3 alongside tesamorelin is straightforward for most patients. The key steps are:

Choose the right form. Over-the-counter fish oil quality varies widely. The International Fish Oil Standards (IFOS) program tests for oxidation, heavy metals, and label accuracy. Patients who want a clinically meaningful TG reduction should aim for a product delivering at least 1 g EPA+DHA per serving, confirmed on the supplement facts panel rather than the "fish oil" total.

Pick a dose based on TG level. Baseline TG between 150 and 300 mg/dL: 1 to 2 g EPA+DHA/day is a reasonable starting dose. TG above 300 mg/dL: a conversation about prescription omega-3 (Vascepa or Lovaza) is appropriate given the stronger evidence base.

Take omega-3 with food. Absorption of EPA and DHA increases by 50 to 70% when taken with a high-fat meal compared with a fasted state [11]. This practical step costs nothing and meaningfully improves efficacy.

Continue tesamorelin injections as prescribed. Tesamorelin is given once daily subcutaneously. Adding omega-3 does not change the injection schedule, the injection site, or the reconstitution protocol.

Report new bruising. At doses above 3 g EPA+DHA/day, patients should mention any unexplained bruising at clinic visits. This is a low-frequency observation, not a contraindication.

Special Populations

Patients on Warfarin

Warfarin users who add prescription omega-3 at 4 g/day should have INR checked within 4 weeks of starting. In a 2009 study (N=42), high-dose omega-3 increased INR by a mean of 0.2 in warfarin-stabilized patients, a clinically small but detectable change [12]. Most warfarin-managed HIV patients are in this position due to atrial fibrillation or venous thromboembolism, not because of tesamorelin.

Patients with Diabetes

Tesamorelin carries a label warning about glucose intolerance, because GH is insulin-antagonistic. The Egrifta SV label notes that new-onset diabetes or worsening of pre-existing diabetes may occur [2]. Omega-3 at standard doses does not worsen glycemia. REDUCE-IT found no significant change in HbA1c in the EPA group relative to placebo after 4.9 years [4]. This combination does not compound the glucose risk.

Patients Already on Statins

Many HIV patients with dyslipidemia are on statins. Adding both tesamorelin and omega-3 to a statin background is common in clinical practice. No pharmacokinetic interactions between omega-3 and commonly used statins (atorvastatin, rosuvastatin, pitavastatin) have been documented at standard doses. The lipid-lowering mechanisms are fully complementary.

Key Takeaway for Patients

Omega-3 (EPA/DHA) can be taken with Egrifta (tesamorelin). No pharmacokinetic interaction exists. The combination may produce more TG reduction than either agent alone, which is typically beneficial. Patients taking anticoagulants and high-dose omega-3 (above 3 g EPA+DHA/day) should notify their prescriber. A fasting lipid panel 6 weeks after starting omega-3 is the one concrete monitoring step that catches both excessive TG lowering and confirms the supplement is working. Patients on tesamorelin 2 mg/day who add 2 g EPA+DHA daily as a prescription or high-quality over-the-counter supplement are following a clinically supported approach to comprehensive lipid management in HIV-associated lipodystrophy.